Prevention strategies in prostate cancer

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Trottier, Greg ^a   Lawrentschuk, N ^a   Fleshner, N E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dutasteride; Finasteride; Nutraceutical; Prevention; Prostate neoplasms; Risk; Statins

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; BIOLOGICAL MARKER; DUTASTERIDE; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYCOPENE; NUTRACEUTICAL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TOREMIFENE; VITAMIN D;

ADVANCED CANCER; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROL STRATEGY; DIET SUPPLEMENTATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EJACULATION DISORDER; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FOLLOW UP; GLEASON SCORE; HEART DISEASE; HIGH RISK POPULATION; HUMAN; MALE SEXUAL DYSFUNCTION; NONHUMAN; PRIMARY PREVENTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SOYBEAN; TEA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 78149452875     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.703     Document Type: Article

References (37)

1. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-19.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (hgpin) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
4. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9.
5. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19:413-25.
6. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179-84.
7. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
8. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of psa for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33.
9. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila PA) 2008;1:174-81.
10. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74.
11. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila PA) 2008;1:182-6.
12. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and highgrade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
13. Kramer BS, Hagerty KL, Justman S, et al. Use of 5-alpha- reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009;27:1502-16.
14. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Costeffectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058-65.
15. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009;55:533-42.
16. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002;62:1370-6.
17. Price D, Stein B, Sieber P, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase iib clinical trial. J Urol 2006;176:965-70.
18. Hamilton RJ, Freedland SJ. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 2008;18:333-9.
19. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
20. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833-43.
21. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
22. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
23. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-17.
24. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-25.
25. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterollowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-32.
26. Lippert MC, McClain R, Boyd JC, Theodorescu D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999;86:2642-8.
27. Syed DN, Suh Y, Afaq F, Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett 2008;265:167-76.
28. Trottier G, Bostrom PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol 2010;7:21-30.
29. Schwartz GG, Hanchette CL. uv, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 2006;17:1091-101.
30. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study ii randomized controlled trial. JAMA 2009;301:52-62.
31. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (select). JAMA 2009;301:39-51.
32. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004;13:340-5.
33. Kirsh VA, Mayne ST, Peters U, et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:92-8.
34. Peters U, Leitzmann MF, Chatterjee N, et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case- control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007;16:962-8.
35. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 2009;89:1155-63.
36. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167:71-7.
37. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54:472-3.